Tumor necrosis factor receptor-associated factor 6 is an intranuclear transcriptional coactivator in osteoclastsOsteoclasts: what do they do and how do they do it?Depression, antidepressants, and bone health in older adults: a systematic reviewRANKL Employs Distinct Binding Modes to Engage RANK and the Osteoprotegerin Decoy ReceptorTherapeutic implications of suppressing osteoclast formation versus functionBone resorption by osteoclastsAdult versus embryonic stem cells: treatmentsA Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast functionSHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclastsUnoccupied alpha(v)beta3 integrin regulates osteoclast apoptosis by transmitting a positive death signalSyk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorptionMouse genome-wide association and systems genetics identify Asxl2 as a regulator of bone mineral density and osteoclastogenesisGenetic regulation of osteoclast development and functionc-Src links a RANK/αvβ3 integrin complex to the osteoclast cytoskeleton.Paxillin contracts the osteoclast cytoskeletonRab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption.Cytoskeletal dysfunction dominates in DAP12-deficient osteoclastsType I phosphotidylinosotol 4-phosphate 5-kinase γ regulates osteoclasts in a bifunctional mannerZap70 inhibits Syk-mediated osteoclast function.Vinculin regulates osteoclast functionSuccessful bone-marrow transplantation for infantile malignant osteopetrosis.Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit.Serotonin-norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption.Defective binding of macrophages to bone in rodent osteomalacia and vitamin D deficiency. In vitro evidence for a cellular defect and altered saccharides in the bone matrix.Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival.Cdc42 regulates bone modeling and remodeling in mice by modulating RANKL/M-CSF signaling and osteoclast polarization.Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults.Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclastsFHL2 inhibits the activated osteoclast in a TRAF6-dependent manner.Microfibril-associated glycoprotein-1, an extracellular matrix regulator of bone remodeling.Osteoclasts, integrins, and osteoporosis.M-CSF mediates TNF-induced inflammatory osteolysisAxial osteomalacia. Clinical, laboratory and genetic investigation of an affected mother and son.Macrophage-colony-stimulating factor regulates expression of the integrins alpha 4 beta 1 and alpha 5 beta 1 by murine bone marrow macrophages.Osteopetrosis.Manipulation of receptor oligomerization as a strategy to inhibit signaling by TNF superfamily membersGlucocorticoids modulate macrophage surface oligosaccharides and their bone binding activity.Spontaneous release of interleukin 1 from human blood monocytes reflects bone formation in idiopathic osteoporosis.Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?Absence of Dap12 and the αvβ3 integrin causes severe osteopetrosis.
P50
Q24651323-A399471E-049E-499A-9266-43AA9C6FDE08Q24683898-44767637-31EC-4E25-8117-052827925B02Q27010527-AA4E1B7B-0729-47B0-9DF8-FA46A1C2F800Q27674275-560E150C-E21F-4BF9-B216-9C2FF4B9C6FAQ28078231-EA91A679-43DE-4389-972A-5A7E792A1265Q28145169-8EA59DA4-D135-46C8-9204-DF8FD2FC0796Q28305541-C8246155-1C59-4024-BC29-D27816B7F5CDQ28364534-E9A341F2-1E16-452A-9FDC-DE7362C57339Q28510858-6BC2C4BD-D51E-40BC-B403-35196779C059Q28512578-189BC53C-35CF-4C45-8753-7EF6E3D83309Q28592760-5DAC3AAD-D203-4538-BDA5-AC4C33B1C14EQ28593424-69D7E259-C7CF-4928-B085-D22EDFE09D4CQ29617421-82F54BC2-FB24-49B9-AB4E-BE8EE7C5686BQ30010102-0C5B4483-5421-4C65-A400-9E036DE32612Q30416067-ABDCF1BD-2984-4E8C-8144-2A7F4F1C964EQ30475918-1254C387-B5E5-4C1C-B7CF-75CFA5D1E0A8Q30496147-475DC534-304F-4620-9991-DEE4C69EDC00Q30536513-00D39943-B03F-4369-A4F1-83B470AE2AA1Q30575570-071C9F73-4749-42F9-89C6-041EE34476B6Q30579060-2ECB60E6-19F4-4E86-B865-D3F1D5702A1AQ33483311-2A7E94D3-0DFF-4A88-B981-CB35B7214E5AQ33752896-4204B8DE-1068-421D-8890-F0A108B0C39AQ33789841-5EE62FA9-27FB-48DF-8359-3DD33A52CA1AQ33822041-208E0FF3-AC18-41EF-B11D-2F262D479256Q33835366-DA29B652-BCCA-4F62-8D2F-54A5B134E3C4Q33882828-AAE8A699-C4AF-40A4-B194-FF962A5452FEQ33900986-8107E454-26FE-4D5C-83D2-5F7FBF20A02DQ33939357-DFA525F2-BD73-4D6D-8C75-F05BB2168D0AQ34014506-F3EE93B0-21D7-4D24-A705-704759C98A4FQ34025344-E7456640-E7E2-4491-AA08-F37F5CB9BB0AQ34071057-CE208D38-9732-4618-93AF-BBC5FB6073E4Q34133595-2517BCD4-C6F2-4100-B647-554BF7BE41BCQ34284491-1A3B6493-7D64-4D76-AEDA-219B8596C8C8Q34295875-78FF08CA-0143-49D7-89B9-6BB2C58FC089Q34380528-E5546F7A-2C2D-4E3F-A141-95AF2CB2FB1FQ34386821-D3B71C62-AA3E-4F04-9EEE-5B65403D14D1Q34609145-A70712A3-04CC-446D-A631-29ADB4E6351CQ34636420-E58ADACD-E2D8-4F2D-B8BC-5E98DC87A3EFQ34753158-8E7EA66C-2BB3-4608-BB21-22D437C286A3Q34825981-D19568AA-8D58-4D44-879D-986A87B2C2B3
P50
description
US-amerikanischer Pathologe
@de
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Steven L Teitelbaum
@nl
Steven L Teitelbaum
@sl
Steven L. Teitelbaum
@de
Steven L. Teitelbaum
@en
Steven L. Teitelbaum
@es
type
label
Steven L Teitelbaum
@nl
Steven L Teitelbaum
@sl
Steven L. Teitelbaum
@de
Steven L. Teitelbaum
@en
Steven L. Teitelbaum
@es
altLabel
Steven Teitelbaum
@de
prefLabel
Steven L Teitelbaum
@nl
Steven L Teitelbaum
@sl
Steven L. Teitelbaum
@de
Steven L. Teitelbaum
@en
Steven L. Teitelbaum
@es
P214
P244
P106
P21
P214
P244
P31
P496
0000-0002-4054-6679
P569
1938-06-29T00:00:00Z
P735
P7859
lccn-n89648572